LearnGlossaryMarketStocksSuperinvestorsSign in

PGEN

Precigen, Inc.

Healthcare · $2.9B market cap

Verdict

We can't put a fair value on PGEN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-30.8% a year✗
Sales growth-10.0% a year✗
Free cash flow growth—?
Return on invested capital-69.0%✗

Follow PGEN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds PGEN. In Q1 2026, 1 sold out. Who we track

Samantha McLemore

Patient Capital Management · as of Q2 2026

$108.5M

19,036,976 shares

Moves in Q1 2026

Sold out: Polen Capital Management

About Precigen, Inc.

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works